News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
760,229 Results
Type
Article (53077)
Company Profile (352)
Press Release (706784)
Multimedia
Podcasts (120)
Webinars (21)
Section
Business (209733)
Career Advice (2063)
Deals (36238)
Drug Delivery (140)
Drug Development (85052)
Employer Resources (174)
FDA (16971)
Job Trends (15288)
News (356404)
Policy (33768)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2773)
Academic (1)
Accelerated approval (51)
Adcomms (34)
Allergies (173)
Alliances (51409)
ALS (217)
Alzheimer's disease (1817)
Antibody-drug conjugate (ADC) (498)
Approvals (17328)
Artificial intelligence (705)
Autoimmune disease (301)
Automation (56)
Bankruptcy (371)
Best Places to Work (11859)
BIOSECURE Act (22)
Biosimilars (225)
Biotechnology (242)
Bladder cancer (206)
Brain cancer (81)
Breast cancer (804)
Cancer (6216)
Cardiovascular disease (484)
Career advice (1752)
Career pathing (43)
CAR-T (353)
CDC (59)
Celiac Disease (3)
Cell therapy (949)
Cervical cancer (49)
Clinical research (73538)
Collaboration (2164)
Company closure (7)
Compensation (1423)
Complete response letters (90)
COVID-19 (2800)
CRISPR (117)
C-suite (1179)
Cystic fibrosis (156)
Data (8090)
Decentralized trials (3)
Denatured (34)
Depression (163)
Dermatology (88)
Diabetes (593)
Diagnostics (7233)
Digital health (57)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (341)
Drug pricing (211)
Drug shortages (31)
Duchenne muscular dystrophy (291)
Earnings (93275)
Editorial (68)
Employer branding (21)
Employer resources (153)
Events (123465)
Executive appointments (1113)
FDA (20776)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1777)
Gene editing (254)
Generative AI (60)
Gene therapy (768)
GLP-1 (1082)
Government (4867)
Grass and pollen (7)
Guidances (408)
Healthcare (19543)
HIV (84)
Huntington's disease (58)
IgA nephropathy (97)
Immunology and inflammation (304)
Immuno-oncology (103)
Indications (196)
Infectious disease (3145)
Inflammatory bowel disease (227)
Inflation Reduction Act (15)
Influenza (137)
Intellectual property (295)
Interviews (324)
IPO (16941)
IRA (51)
Job creations (3749)
Job search strategy (1457)
JPM (64)
Kidney cancer (21)
Labor market (102)
Layoffs (603)
Leadership (40)
Legal (8192)
Liver cancer (108)
Longevity (32)
Lung cancer (815)
Lymphoma (436)
Machine learning (61)
Management (59)
Manufacturing (1075)
MASH (195)
Medical device (14059)
Medtech (14188)
Mergers & acquisitions (20545)
Metabolic disorders (1533)
mRNA (235)
Multiple sclerosis (189)
NASH (17)
Neurodegenerative disease (426)
Neuropsychiatric disorders (109)
Neuroscience (3357)
Neurotech (1)
NextGen: Class of 2026 (6756)
Non-profit (4713)
Now hiring (78)
Obesity (719)
Opinion (309)
Ovarian cancer (231)
Pain (262)
Pancreatic cancer (322)
Parkinson's disease (368)
Partnered (33)
Patents (609)
Patient recruitment (692)
Peanut (62)
People (61098)
Pharmaceutical (66)
Pharmacy benefit managers (32)
Phase 1 (23025)
Phase 2 (32266)
Phase 3 (24051)
Pipeline (8968)
Policy (334)
Postmarket research (2820)
Preclinical (9999)
Press Release (67)
Prostate cancer (324)
Psychedelics (58)
Radiopharmaceuticals (347)
Rare diseases (1139)
Real estate (6134)
Recruiting (70)
Regulatory (26253)
Reports (56)
Research institute (2587)
Resumes & cover letters (356)
Rett syndrome (39)
RNA editing (25)
RSV (89)
Schizophrenia (177)
Series A (296)
Series B (219)
Service/supplier (12)
Sickle cell disease (120)
Special edition (27)
Spinal muscular atrophy (177)
Sponsored (50)
Startups (3815)
State (2)
Stomach cancer (21)
Supply chain (128)
Tariffs (90)
The Weekly (83)
Vaccines (1144)
Venture capital (113)
Weight loss (467)
Women's health (128)
Worklife (20)
Date
Today (119)
Last 7 days (693)
Last 30 days (3620)
Last 365 days (30900)
2026 (13239)
2025 (30922)
2024 (36097)
2023 (40956)
2022 (52221)
2021 (56779)
2020 (55086)
2019 (47719)
2018 (35968)
2017 (33330)
2016 (32834)
2015 (38837)
2014 (32633)
2013 (28046)
2012 (30314)
2011 (30854)
2010 (29172)
Location
Africa (792)
Alabama (93)
Alaska (7)
Arizona (357)
Arkansas (14)
Asia (42103)
Australia (7090)
California (13551)
Canada (3814)
China (1397)
Colorado (576)
Connecticut (589)
Delaware (412)
Europe (93593)
Florida (2014)
Georgia (432)
Hawaii (3)
Idaho (63)
Illinois (1073)
India (90)
Indiana (607)
Iowa (24)
Japan (547)
Kansas (134)
Kentucky (51)
Louisiana (42)
Maine (76)
Maryland (1633)
Massachusetts (9702)
Michigan (368)
Minnesota (737)
Mississippi (6)
Missouri (147)
Montana (36)
Nebraska (29)
Nevada (143)
New Hampshire (85)
New Jersey (3557)
New Mexico (31)
New York (3547)
North Carolina (1725)
North Dakota (10)
Northern California (6779)
Ohio (403)
Oklahoma (23)
Oregon (45)
Pennsylvania (2726)
Puerto Rico (29)
Rhode Island (50)
South America (1166)
South Carolina (87)
South Dakota (2)
Southern California (5335)
Tennessee (216)
Texas (2157)
United States (47844)
Utah (404)
Vermont (1)
Virginia (324)
Washington D.C. (80)
Washington State (1099)
West Virginia (4)
Wisconsin (143)
Wyoming (2)
760,229 Results for "cancer genetics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
May 13, 2026
·
6 min read
Press Releases
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
April 14, 2026
·
3 min read
Pancreatic cancer
Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes
Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients.
May 18, 2026
·
7 min read
·
Heather McKenzie
Press Releases
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
April 10, 2026
·
4 min read
Press Releases
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
May 14, 2026
·
3 min read
Press Releases
SignaBlok to Present Novel Approach to Preventing Cancer Recurrence at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Ligand-independent mechanism of action of SignaBlok’s first-in-class TREM-1 inhibitors enables development of cell-unspecific and macrophage-targeted TREM-1 inhibitors · In experimental pancreatic cancer, macrophage-targeted but not cell-unspecific TREM-1 inhibitor: − prevents cancer recurrence, improves complete response rate and survival, when administered in a time window of 7 days after standard-of-care (SOC) chemotherapy − reverses immunosuppression and overcomes cancer resistance to anti-PD-L1 immunotherapy · Timely resolution of acute inflammation induced by SOC cancer treatments (chemotherapy, surgery, radiation, radiopharmaceuticals, etc.) can be a common approach to prevent cancer recurrence, increase response rate and survival for not only pancreatic cancer but also other hard-to-treat tumors
March 26, 2026
·
1 min read
Complete response letters
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did not flag problems with the drug’s efficacy or safety.
March 9, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
April 16, 2026
·
5 min read
Press Releases
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
May 6, 2026
·
25 min read
Podcast
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
Johnson and Johnson kicked off first-quarter earnings season with a “modest” beat and an ambitious goal; Replimune failed again to gain approval for its advanced melanoma therapy, as analysts tout increased accountability brought by the FDA’s new policy of publicizing complete response letters; and Revolution Medicines’ pancreatic cancer candidate doubled survival in one of cancer’s most intractable foes.
April 15, 2026
·
1 min read
·
Heather McKenzie
1 of 76,023
Next